WO1996026745A1 - Vecteurs de virus biosynthetiques a usage en therapie genique - Google Patents

Vecteurs de virus biosynthetiques a usage en therapie genique Download PDF

Info

Publication number
WO1996026745A1
WO1996026745A1 PCT/US1996/002877 US9602877W WO9626745A1 WO 1996026745 A1 WO1996026745 A1 WO 1996026745A1 US 9602877 W US9602877 W US 9602877W WO 9626745 A1 WO9626745 A1 WO 9626745A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
nucleic acid
molecule
delivery composition
gene delivery
Prior art date
Application number
PCT/US1996/002877
Other languages
English (en)
Other versions
WO1996026745A9 (fr
Inventor
Clague P. Hodgson
Original Assignee
Nature Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nature Technology Corporation filed Critical Nature Technology Corporation
Priority to EP96907918A priority Critical patent/EP0824362A1/fr
Priority to AU51353/96A priority patent/AU5135396A/en
Publication of WO1996026745A1 publication Critical patent/WO1996026745A1/fr
Publication of WO1996026745A9 publication Critical patent/WO1996026745A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention relates to the fields of gene therapy, gene transfer, transgenic organisms and gene expression.
  • Transfection refers to the use of physical or chemical methods of insertion, which includes microinjection, microparticle bombardment, liposomal preparations, or electroporation, among others.
  • Transduction refers to the use of viral particles or viral mechanisms to gain entry into the cell. The advantage of transfection is that it is relatively safe and efficient - up to 90% or more of transfected cells can express the gene for a limited time. In general, such expression is limited to 2-3 days but can persist for longer periods as well.
  • transient transfection techniques have no efficient mechanism for transfected DNA to be maintained in the cell.
  • retroviral transduction allows the insertion of genes directly into the genome where they can be maintained, and potentially expressed, for a much longer time.
  • Transduction by certain DNA viruses also allow transduced genes to be replicated in an autonomous fashion, resulting in their pe ⁇ etuation over a period of time.
  • transduction of cells by any virus often results in the production of replication-competent viruses, which pose a threat to the host.
  • transduction by DNA viruses, as opposed to retroviruses. often requires the expression of one or more viral genes to perpetuate the viral replication process in vivo. Viral replication activates the host immune system and results in the elimination or rejection of the virally transduced cells.
  • viral expression in vivo often decreases or ends altogether within a relatively short time.
  • retrotransposon vectors see Hodgson, U.S. Patent No. 5,354,674
  • synthetic vectors see WO94/20608
  • improved the safety and efficiency of gene transfer by removing homology to viral sequences, which improves safety, and by providing a source of transcriptional promoters and enhancers, which improves expression.
  • retroviral virion-based systems continued to use retroviral virion-based systems to deliver the genes into cells, which necessitates significant testing of such reagents prior to administering them to humans.
  • the risk of viral recombination between the vector and virus-related sequences which leads to replication-competent virus, was decreased by reducing the homology between the vector and helper sequences to near zero, virion-based delivery systems remain problematic.
  • retro-vectors are of little usefulness in vivo, because of the rapid inactivation of retroviral particles by serum proteins.
  • the majority of current gene therapies which employ retroviral virion-based gene transfer must take place in the ex vivo setting, i.e., in culture, followed by cell transplantation.
  • the efficiency of retroviral vector transfer into cells needs to be improved. That is, it would be desirable to increase the efficiency of gene delivery by retroviral helper cells by one to two orders of magnitude, as well as to expand or target the repertoire of cells that can be infected, and to prevent the serum inactivation which takes place in vivo.
  • Various approaches to solving these problems have been attempted.
  • Rubin et al. (U.S. Patent No. 4,670,388) delivered a DNA segment containing integration sites recognized by a Drosophila derived transposase and another DNA segment which encoded the transposase into cells. They found that the DNA containing the integration sites was inserted into the genomic DNA.
  • a similar method was used to deliver genes into the yeast genome via Ty retrotransposons (Boeke et al., Science. 239, 280 (1988)).
  • Ty retrotransposons Boeke et al., Science. 239, 280 (1988)
  • viral delivery and/or expression can be enhanced by physical or chemical transfection methods.
  • physical or chemical transfection methods For example, Curiel et al. /Proc. Natl. Acad. Sci. USA. 88, 8850 (1991)) mixed inactivated adenovirus particles and DNA and added the mixture to cells. The mixture entered cells by receptor mediated endocytosis. Once inside the endosome, the first vesicle after entrapment, adenovirus proteins associated with the viral capsid disrupted the endosome vesicle in response to acidification of the endosome and ejected the DNA into the cytoplasm.
  • Wu et al. disclose the covalent modification of the surface of retroviruses. The molecule which was covalently bound to the retrovirus binds to receptors on a particular cell surface. Wu et al. also disclose that the injection of a mixture of DNA and poly L-lysine terminated with asialo-orosomucoid resulted in specific uptake and transient expression of the DNA by liver hepatocytes, which have a receptor for asialoglycoprotein. Jolly et al. (WO92/05266) disclose the modification of envelope proteins and other ligands located on the surface of virions to permit the selective entry of those modified proteins and ligands into cells.
  • Liposomal preparations have been used for drug delivery and as delivery vehicles.
  • Several commercial liposomal preparations are available for the delivery of DNA and RNA to cells for transient expression, as well as for inefficient, stable expression.
  • Such commercial products include LipofectinTM (Gibco-BRL, Inc., Gaithersberg, MD), LipofectamineTM (Gibco-BRL, Gaithersberg, MD), and DOTAPTM (Boehringer Mannheim).
  • these commercial preparations consist of various cationic lipid preparations, together with an approximately equimolar amount of neutral lipid. The cationic lipid is thought to interact with the neutral lipid to facilitate charge balancing.
  • the lipids are usually mixed in an organic solvent, dried under vacuum, and resuspended in aqueous solution by vortexing, homogenization, or sonication prior to use or vending.
  • the aqueous preparations consist of small unilamellar vesicles and large multilamellar vesicles which can be mixed with nucleic acids according to the manufacturer's instructions.
  • Liposomes can also be modified through the covalent or non- covalent addition of ligands, such as antibodies (Micklus, WO94/02178), which give added specificity to the entry of such liposomal compositions into selective cells.
  • ligands such as antibodies (Micklus, WO94/02178)
  • Shoji-Tanaka et al. reported the liposomal-based delivery of integrase enzyme and a DNA substrate intended for integration into cells. The authors claimed to have achieved specific integration of the substrate DNA at a slightly enhanced rate (3-5 fold) for the liposomal preparation with the integrase and DNA substrate relative to a liposomal preparation of DNA substrate alone.
  • the substrate employed by Shoji-Tanaka did not contain the correct recognition signal for integrase. i.e., they employed only one LTR terminus rather than two LTRs. or the correct physical form of the substrate, i.e., they employed a circular DNA substrate rather than a linear DNA substrate.
  • Lamellar liposomes have been used to infect resistant cells with
  • the present invention provides gene delivery compositions and methods for introducing the claimed compositions into cells.
  • the gene delivery compositions of the invention comprise a liposomal preparation, a nucleic acid molecule, and a perpetuation molecule.
  • the liposomal preparations of the invention augment or replace functions associated with viral gene transfer.
  • the liposomal preparations of the invention preferably comprise a cationic lipid moiety, preferably a polycationic lipid moiety.
  • Cationic lipid moieties useful in the practice of the invention include, but are not limited to, DOSPA, DMRIE, DOTAP, DOGS. DOTMA, DDAB, L-PE, a starburst dendrimer, or a starburst dendrimer covalently or noncovalently associated with an acyi moiety which can serve as an anchor to a biological membrane (e.g., a diacyl glycerol with a linking moiety, such as phosphatidyl serine).
  • a preferred embodiment of the invention is a cationic lipid moiety selected from the group consisting of DOSPA. DOTAP, DOTMA, DDAB and L-PE.
  • Another embodiment of the invention is a liposomal preparation having a cationic lipid moiety and a neutral lipid moiety.
  • a neutral lipid moiety useful in the practice of the invention includes, but is not limited to, phosphatidyl ethanolamine. phosphatidyl inositol, dioleylphosphatidyl ethanolamine (DOPE), cholesterol, and their analogs or derivatives.
  • the liposomal preparation of the present invention can be a unilamellar vesicle, a cytofectin, a multilamellar vesicle or other naturally occurring lipid particle.
  • a preferred embodiment of the invention includes a liposomal preparation comprising a lipid moiety and a cellular protein which facilitates and/or enhances entry or trafficking of the gene delivery composition in the cell, such as a cell receptor ligand, a cell receptor, an antibody, a portion of an antibody, a T cell receptor, a glycoprotein, a chimeric protein and/or an asialoglycoprotein.
  • Protenoids such as PODDS and CADDSYS compounds (U.S. Patent 4,925,673) can also be combined, covalently or noncovalently, with the liposomal preparations to enhance cellular uptake.
  • the gene delivery compositions of the invention comprise a nucleic acid molecule which comprises a chimeric gene.
  • the nucleic acid molecule of the invention can be associated with at least one purified viral particle.
  • a preferred embodiment of the invention is a gene delivery composition comprising a liposomal preparation and a viral particle, preferably a modified or inactivated viral particle.
  • the viral particle can be inactivated by physical or chemical treatment, or the viral capsid of the viral particle can be modified by partially or completely disrupting the capsid.
  • purified viral components can be used in place of any portion of the virus particle.
  • molecules derived from non-viral mobile genetic elements and/or cells can be substituted for such viral components.
  • a purified viral particle useful in the practice of the invention includes, but is not limited to, an enveloped RNA virus, such as a retrovirus, a retrotransposon pseudotyped into a retrovirus, a synthetic retroelement, or other RNA viruses, or a DNA virus, such as a poxvirus, a hepadnavirus, an adenovirus. a he ⁇ es virus and the like, or a caulimovirus and the like.
  • the virus is preferably an enveloped virus containing negatively charged phospholipids in its outer shell.
  • the nucleic acid molecule of the present invention can further comprise integration signals.
  • a preferred embodiment of an integration signal useful in the practice of the invention includes, but is not limited to, retroviral attachment (att) or integration sites, parvovirus inverted terminal repeats, transposase recognition sites, retrotranpsoson recognition sites, retroelement recognition sites, retrotransposon reverse transcriptase recognition sites, and integrase recognition sites.
  • retroviral attachment or integration sites include those derived from: Moloney murine leukemia virus, avian sarcoma- leukosis virus, spleen necrosis virus, HIV1, HIV2, reticuloendotheliosis virus, avian myeloblastosis virus, HTLV-1, HTLV-2, lentiviruses, and oncoretroviruses.
  • useful integration signals include those recognized by the integrase and transposase enzymes of bacterial transposons, eukaryotic transposons such as Drosophila P elements, and the integrative sequences of phages such as Mu, lambda, the phages of E. coli, as well as parvovirus inverted terminal repeats.
  • the gene delivery compositions of the invention further comprise at least one pe ⁇ etuation molecule, or a nucleic acid molecule which encodes a pe ⁇ etuation molecule.
  • the pe ⁇ etuation molecule permits the persistence of the chimeric gene within the cell, either as an element which is integrated into the genome of the cell or through autonomous replication of the gene in the cell.
  • a preferred pe ⁇ etuation molecule of the invention is a pe ⁇ etuation protein.
  • a pe ⁇ etuation protein of the invention includes, but is not limited to, a retroviral reverse transcriptase, an integrase, such as a retroviral integrase, Moloney murine leukemia virus reverse transcriptase, avian myeloblastosis virus reverse transcriptase, avian leukosis-sarcoma virus reverse transcriptase, spleen necrosis virus reverse transcriptase, reticuloendotheliosis virus reverse transcriptase, HIV1 reverse transcriptase, or HIV2 reverse transcriptase, parvovirus rep protein, adenovirus associated virus rep protein, bacterial transposon transposase.
  • a retroviral reverse transcriptase such as a retroviral integrase, Moloney murine leukemia virus reverse transcriptase, avian myeloblastosis virus reverse transcriptase, avian leukosis-sarcoma virus reverse transcriptase,
  • bacterial integron integrase eukaryotic integrase from DNA-based mobile genetic elements and Drosophila P element transposase, and other such molecules which permit integration and/or autonomous maintenance of a gene which is co-introduced with the perpetuation molecule within the cell.
  • pe ⁇ etuation molecule of the invention include nuclear transport proteins or peptides, retroviral matrix protein, HIV virus matrix protein, nuclear localization signals of the subclasses illustrated by SV40 large T antigen nuclear localization signal, nuclear localization signals of the subclasses illustrated by polycationic polypeptides, poly-ornithine and the like.
  • a cellular recombinase such as the E. coli recA protein.
  • a preferred embodiment of the pe ⁇ etuation molecule of the invention is a pe ⁇ etuation protein which is tethered to a peptide or the nucleic acid molecule of the invention to maintain proximity of the peptide or nucleic acid molecule to the pe ⁇ etuation protein.
  • the tether can comprise a linking molecule, such as an ester, polypeptide, antibody, avidin, streptavidin, biotin, or other molecule attached covalently, or through electrostatic, hydrophobic, ionic, van der waals, affinity, or other chemical interactions, so as to promote maintenance of the tethered complex during entry, transport, integration, and/or maintenance within the cell.
  • the present invention also provides a method of delivering a gene to a cell which employs the gene delivery compositions described hereinabove.
  • FIG. 1 A schematic representation of a gene delivery composition comprising (i) a liposome which comprises cationic lipids, and (ii) an isolated enveloped virus which contains a nucleic acid molecule (genome) and a pe ⁇ etuation molecule (reverse transcriptase). The positive charge on the lipid neutralizes some or all of the negative charge associated with the viral envelope, increasing the affinity of the envelope glycoprotein or its equivalent for its cognate cellular ligand.
  • B A schematic representation of a gene delivery composition comprising an isolated virus particle enclosed within a multilamellar liposome.
  • C A schematic representation of a gene delivery composition comprising (i) a nucleic acid molecule which comprises a therapeutic gene, integration (att) and packaging sequences ( ⁇ ).
  • a schematic representation of a gene delivery composition comprising (i) an isolated virus particle, (ii) a liposome comprising cationic lipid, and (iii) DNA segments present on the exterior of the virus particle.
  • Cationic lipids are used to adhere the DNA sequences of interest to the viral particle, while increasing the efficiency of infection of the virus vector.
  • the virus/liposome thus allows the DNA to fuse efficiently to the cell, and in addition, integrase may introduce the sequences into the genome (if the proper att signals are present). Viral packaging signals and other response elements may also be present in the DNA to increase its affinity to viral proteins.
  • FIG. 3 A schematic representation of lipid and cationic molecules.
  • the dendrimer refers to a prototype, polyamidoamine (PAMAM) cascade polymer, wherein a nitrogen nucleus at the center seeds the aggregation of three additional dendrites, each terminated with a nitrogen that serves as a source of further dendrimer growth.
  • PAMAM polyamidoamine
  • BI A schematic representation of the BAG vector.
  • a schematic representation of the DNA vector containing the puro-r gene, pl and p2 refer to the primers of Figure 2D, used to amplify the ⁇ -SV-puro-r fragment of approximately 1.5 kb.
  • C Dose response curves for different cytofectins in enhancing efficiency of BAG vector transduction of human HT1080 cells. The number of transduced HT1080 cells ( ⁇ -gal titer) is shown on the Y-axis, as assayed by direct visualization of ⁇ -gal activity (X-gal substrate staining). DOTAP, DOTMA/DOPE and DOSPA/DOPE were used as received from the manufacturers. Concentrations refer to the actual cation concentration, and represent the concentration after application to HT1080 cell monolayers.
  • Liposomal preparations carrying various drugs and DNA have been used with success in vivo by injection (Debs et al., WO93/25673), and are currently in use for gene therapy clinical trials for nucleic acid delivery both ex vivo and in vivo (summarized In: The Internet book of Gene Therapy Cancer Therapeutics, Sobol and Scanlon. eds.. Appleton and Lange, pp. 283- 296 (1995)).
  • the capability of liposomal preparations to more effectively deliver virus particles and biosynthetic viruses can now be exploited for stable introduction of genes into cells and tissues.
  • Lamellar liposomes ( Figure 1 B) provide a particulate coat against in vivo inactivation of virus by human serum, and provide a possible alternative route for infection (receptor mediated endocytosis).
  • the previous inability of retrovirus capsids to package more than 10 kb nucleic acid molecules can now be overcome by using a lamellar biosynthetic virus ( Figure IC), or by using a virus particle with a nucleic acid molecule which is associated by means of liposomes ( Figure ID).
  • Figure ID lamellar biosynthetic virus
  • the present invention relates to a composition of matter comprising a synthetic lipid (liposomal preparations) together with either virus particles or other materials for the introduction and long-term maintenance of genetic material in host and/or recipient cells, tissues, or organisms.
  • Other materials which may be included in the composition are nucleic acids, enzymes, ribozymes, proteins, peptide signal sequences, antibodies and the like which are used for helping to introduce the DNA into the genome of the recipient cell.
  • the nucleic acid molecule of the invention may contain recognition signals which are sufficient for integration of the nucleic acid molecule of the invention by means of the enzymes or other materials provided.
  • the nucleic acid molecule may also contain transcriptional promoters, enhancers, matrix attachment regions, locus determining elements, boundary elements and other control elements such as response elements for transcription factors.
  • the nucleic acid molecule may also contain any of a variety of genetic sequences such as protein encoding sequences, ribozyme encoding sequences, antisense, triplex forming regions, introns, exons, etc. intended for therapeutic gene expression.
  • the liposomal preparations include, but are not limited to, cytofectins, multilamellar vesicles and unilamellar vesicles.
  • a preferred embodiment of the invention is a liposomal preparation which comprises 50% cationic lipid, preferably a polycation such as DOSPA. and 50% neutral lipid. preferably DOPE.
  • Commercially available lipid materials useful in the practice of the invention include LipofectamineTM (DOSPA:DOPE. Gibco BRL). LipofectinTM (DOTMA:DOPE, Boehringer Mannheim), and DOTAPTM (Boehringer Mannheim), and the like. Such polycationic lipids greatly enhance transduction efficiency.
  • the gene delivery compositions of the invention provide a synthetic, virus-like particle, or a composition comprising a virus particle and a liposomal preparation which can neutralize the negative charges associated with biological membranes, such as viral envelopes and plasma membranes.
  • the virus may be modified, for example, by irradiation, e.g.. to inactivate nucleic acids, or by partial disruption, e.g.. to release enzymes.
  • the viral particle would adhere to the cell via receptor ligands such as proteins or glycoproteins. leading to uptake of the virus by the cell, sometimes by the process of direct cytoplasmic entry, or in the case of lamellar liposomes, by receptor-mediated endocytosis.
  • receptor ligands such as proteins or glycoproteins. leading to uptake of the virus by the cell, sometimes by the process of direct cytoplasmic entry, or in the case of lamellar liposomes, by receptor-mediated endocytosis.
  • a gene delivery composition which comprises a liposomal preparation comprising a cationic lipid moiety, preferably a polycationic moiety, is added to viral particles which comprise a chimeric gene and a pe ⁇ etuation molecule, or to cells, or both, to neutralize the net negative surface charge on virus and/or cell membranes, so as to enhance the efficiency of infection by at least about a hundred fold or more.
  • the viral particle enters the cell by its normal route, e.g., cytoplasmic fusion, which is restricted to the tropism of the virus.
  • Yet another embodiment of the invention is a gene delivery composition
  • a lamellar liposomal preparation preferably a multilamellar liposomal preparation, and a viral particle.
  • the viral particle comprises a nucleic acid molecule, which comprises a chimeric gene, and a pe ⁇ etuation molecule.
  • This gene delivery composition permits the viral particle to infect cells via endosomal uptake, bypassing the usual tropism of the virus.
  • this gene delivery composition permits the virus to remain unrecognized by inactivating serum proteins, i.e., it is masked from complement recognition by the liposomal enclosure. Gene therapy is a new use for such lamellar liposomes.
  • a gene delivery composition of the invention comprises a liposomal preparation, a nucleic acid molecule which comprises a chimeric gene, and at least one pe ⁇ etuation molecule.
  • a preferred embodiment of the invention includes a linear nucleic acid molecule.
  • a more preferred embodiment of the invention is a linear nucleic acid molecule which comprises sequences which encode integration signals.
  • This embodiment of the invention enhances the safety of gene delivery, because intact viral particles are not delivered, although the advantage of pe ⁇ etuation is retained.
  • this embodiment of the invention can include a number of molecules which can affect the efficiency of gene delivery.
  • Cellular targeting molecule(s) such as an antibody.
  • protenoid or ligand for a cellular receptor can be attached to the outside of the gene delivery composition, preferably attached to the liposomal preparation.
  • useful materials that can be combined with the nucleic acid and pe ⁇ etuation molecule(s) and liposomal preparation include peptide trafficking signals, viral capsid proteins, or intact capsids to permit accurate transport out of the endosome (endosmolytic peptides such as those derived from adenovirus, influenza virus, hemagglutinin and retrovirus capsids, from cationic lipids or protenoids) or into the nucleus (nuclear localization signals), as well as for packaging DNA.
  • polycations such as poly L- lysine or polyomithine can be used to wrap the negatively charged DNA, and to reduce the charge so that it can be packaged more efficiently and compactly by the liposomes.
  • Polycationic materials such as the lysine and ornithine polymers mentioned above can also be used as a means to tether the peptide signals (such as endosmolytic or nuclear localization signals, or other proteinaceous materials thereto attached) to DNA. This is a non-covalent, electrostatic attachment.
  • Integrase or transposase enzyme can also be non ⁇ covalently tethered to DNA in this fashion, or it can be covalently attached to the DNA via a linker, such as a peptide, ester, acyi chain, or other covalent linkage.
  • a linker such as a peptide, ester, acyi chain, or other covalent linkage.
  • An example of such a linkage is shown in Figure IC.
  • lipid preferably a polycationic lipid, such as DOSPA:DOPE
  • enveloped viral particles preferably retrovirus particles
  • the cationic lipid may enhance the infectivity of the virus, further aiding efficient penetration of the nucleic acid into the cytoplasm.
  • the DNA may also become integrated via the integrase enzyme associated with the virus if it has terminal att (attachment/integration) sites ( Figure 2), thus facilitating pe ⁇ etuation of the nucleic acid.
  • the nucleic acid molecule can comprise viral encapsidation signals ( ⁇ ) to enhance the affinity of the entire complex.
  • Example 1 Cationic lipid/virus
  • a cationic lipid such as a polycationic lipid preparation, e.g., DOSPA:DOPE ( Figure 3A)
  • virus or vector e.g., the retroviral BAG vector shown in Figure 3 A
  • the transduction efficiency of the vector was greatly enhanced in a dose dependent manner ( Figure 3B).
  • the level of transduction, as determined by the ⁇ -galactosidase titer of either retrovirus alone (-V) or with 6 ⁇ g/ml of hexadimethrine bromide (polybrene, - P) is shown to the left of the graph.
  • polycationic lipid Lipofectamine
  • DOSPA:DOPE was more effective (>60-fold improvement over virus alone) than either DOTMA: DOPE (37-fold) or DOTAP alone (5-fold).
  • DOSPA:DOPE is polycationic.
  • polybrene a polycation with no lipid moiety
  • Figure 3B The transduction efficiency of polybrene, a polycation with no lipid moiety, was compared to that of cationic lipids.
  • Polybrene although polycationic, was approximately ten times less efficient in promoting transduction than DOSPA:DOPE.
  • the enhanced transduction efficiency is proportional to the polycationic charge.
  • the membrane anchoring moiety may also contribute to the enhanced transduction efficiency.
  • lipid compositions comprising the retroviral BAG vector were mixed with human HT1080 cells. Transduced colonies were selected with the drug G418. Cells treated with Lipofectamine had more than 100-fold more G418 resistant colonies than cells exposed to virus alone, demonstrating that the expression of the transduced gene is associated with integration of the vector which contains the gene.
  • the data shown in Figure 3C indicate the usefulness of combining a polycation (as opposed to a monocation) with a membrane anchoring moiety, thus the combination of a large polycation, such as a starburst dendrimer, with a membrane anchoring moiety, which is either covalently or noncovalently attached, or with a neutral lipid, or both, enhances viral vector transduction.
  • a large polycation such as a starburst dendrimer
  • a membrane anchoring moiety which is either covalently or noncovalently attached, or with a neutral lipid, or both
  • large polycations such as DEAE-dextran or polybrene that were formerly used alone, can be used in combination with lipid moieties, to enhance viral vector transductions.
  • the combination may exert the enhanced transduction effect by stabilizing their complexes with negatively charged virus particles.
  • Figure 4A demonstrates that the addition of polybrene alone or in combination with lipid, to virus/cells does not further enhance transduction over DOSPA:DPE treatment alone. If charge neutralization by polycations is the major effector of more efficient transduction, then addition of polybrene to Iipid-virus would be expected to have little if any additive effect over and above the more effective cationic lipids.
  • Figure 4A demonstrates the effect of adding polybrene (alone or in combination with lipid) to virus/cells. It is clear that polybrene gives no additional enhancement of transduction over DOSPA:DOPE treatment alone.
  • Cationic amphiphiles enhance envelope glycoprotein-mediated cellular uptake of retrovirus.
  • cationic receptors which are known to facilitate receptor-mediated endocytosis of lamellar liposomes, could substitute for the retroviral envelope glycoprotein in promoting attachment of virus to cells.
  • GP/BAG ecotropic BAG vector derived from the GP+env86 cell line
  • PA317 helper cells the amphotropic PA317/BAG helper cell line
  • DOSPA:DOPE This treatment resulted in an enhancement of titer equivalent to. or greater than, that seen when virus alone was treated (Figure 4C).
  • the antimalarial drug, chloroquine was added in various combinations to the cells, virus, and lipid-virus compositions. Chloroquine is endosmotropic. facilitating the non-degradative route during receptor-mediated endocytosis (Feigner et al., J. Biol. Chem.. 269. 2550 (1994)). However, no positive effect resulted from any of the chloroquine treatments (Figure 4D), suggesting that receptor- mediated endocytosis was not the predominant route of uptake. Together these experiments indicated that direct cellular uptake by the normal, envelope glycoprotein-mediated cellular fusion mechanism was responsible for infection, and that, unlike the previous experiments with lamellar liposomes. charge neutralization was the likely mechanism of transduction enhancement.
  • Example 2 Lamellar liposomes To determine whether lamellar liposomes enhance viral transduction.
  • virus is introduced into a lamellar liposome. such as a multilamellar liposome.
  • the liposomal preparation may also include other molecules, which are either covalently or non-covalently attached to the liposomal preparation, such as a receptor or ligand for attachment to specific cells.
  • the gene delivery composition of the invention which comprises the lamellar liposomal preparation may enter cells by receptor-mediated endocytosis, via cationic lipid receptors on the cell surface.
  • the gene delivery composition of this embodiment of the invention prevents inactivation of the virus particle by virus-inactivating complement proteins which are present in human serum.
  • the gene delivery composition of this embodiment of the invention also permits introduction of a vector into cells outside the normal host range of the vector through cationic lipid receptors or by interactions between the cell surface and other molecules associated with the liposomal preparation.
  • Example 3 A synthetic viral particle A chimeric nucleic acid molecule is inco ⁇ orated into a gene delivery composition of the invention by combining the nucleic acid molecule with a retroviral integrase enzyme and a liposomal preparation.
  • the integrase enzyme may be derived from Moloney Murine Leukemia Virus, Spleen Necrosis Virus, Reticuloendotheliosis Virus, Avian Sarcoma-Leukosis Virus, Human Immunodeficiency Viruses 1 and 2, Human T Cell Leukemia Viruses 1 and 2, or Avian Myeloblastosis Virus, among others.
  • the att sequence includes two nucleotides which are ordinarily cleaved off the att sequence during integrase-mediated integration.
  • the nucleic acid molecule is a linear DNA molecule such as a cloned fragment or, or a gene amplification product.
  • two att sites are present per nucleic acid molecule, preferably at the ends of the nucleic acid molecule.
  • Other signals such as packaging signals may be used to selectively enhance the uptake and integration by integrase.
  • Providing a double-stranded DNA molecule as the nucleic acid molecule eliminates the requirement for reverse transcriptase enzyme activity, other than its associated integrase activity. It may or may not be desirable to include a viral packaging signal, depending upon the specific requirement of the system being used.
  • Integrase is located at the carboxy terminus of reverse transcriptase enzymes associated with retroviruses, and is functional either as a reverse transcriptase protein cleavage product or as a part of an intact reverse transcriptase, depending upon the virus or retroelement. Integrase can be made by recombinant DNA methods (Craigie et al., Cell, 6, 829 (1990)), or it can be provided by reverse transcriptase enzyme containing the IN coding region. Reverse transcriptase is also available from commercial suppliers of enzymes, although some commercial products contain IN, while other products have been modified by recombinant DNA technology to eliminate IN activity.
  • Reverse transcriptase and integrase activities can also be isolated from virus by standard methods, or virus preparations can be disrupted to provide these activities, (e.g., by gentle detergent lysis, see Goff et al., J. Virol., 38, 239 ( 1981 )) and the crude preparations can be added to the liposomes.
  • Each IN protein has its own recognition signal ( ⁇ tt) at the end of the DNA molecule, which can be determined from the sequence of the cognate virus or retroelement.
  • the recognition signals consist of the inverted terminal repeat at the ends of the long terminal repeats, and occasionally extended sequences beyond the inverted terminal repeat. Usually, from 15-45 bp are required for efficient integration by different viruses.
  • Two of the most commonly available viral enzymes are Moloney Murine Leukemia Virus reverse transcriptase and Avian Myeloblastosis Virus reverse transcriptase.
  • Moloney Murine Leukemia Virus reverse transcriptase can be made by purifying it from virions of cells such as PA317 (available from the American Type Culture Collection (ATCC), Rockville, MD, accession # CRL9078), or any similar cell line producing virus.
  • the virus can be purified by precipitation with ammonium sulfate and concentrated on a sucrose step gradient using the procedure of Fan et al. (J. Mol. Bio.. 80, 93 (1973)), as modified by Fujiwara et al. (Proc. Natl. Acad. Sci. USA. 86, 3065 ( 1989)).
  • the enzyme extract can be obtained as described by Fujiwara et al., using gentle lysis of the viral particles.
  • a preferred method to obtain integrase is to employ recombinant DNA techniques (Craigie et al., Cell, 6, 829 (1990)). Avian myeloblastosis virus reverse transcriptase can be obtained commercially (from Life Sciences, Inc., St. Petersberg, Florida).
  • the nucleic acid molecule of the invention comprises a chimeric gene(s) together with the attachment or integration signals recognized by the preferred enzyme (transposase, resolvase, or retroviral integrase).
  • a preferred form of the nucleic acid molecule is DNA, preferably linear DNA, a preferred substrate for integrase.
  • a nuclear acid molecule which contains a chimeric gene(s) of interest is identified, isolated and/or constructed using standard recombinant DNA techniques.
  • the sequences of interest can also be isolated by gene-amplification, by a method such as the polymerase chain reaction, directly from genomic DNA. To amplify a particular sequence primer molecules are constructed that contain sequences complementary to the flanking sequences of the foreign gene of interest, and sequences recognized by IN protein at the termini of each primer.
  • the integration enzyme may be that of a phage. transposon, insertion element, bacteria or mobile genetic element.
  • the E. coli recA protein or a similar recombinase may be combined with the vector in order to increase the efficiency of site-specific recombination.
  • the primers are used to amplify the sequence of interest using a thermal cycler such as the Perkin Elmer Co ⁇ . (Emeryville, CA) Tempcycler 2400, or Tempcycler 9600, using an enzyme of great fidelity, such as Pfu polymerase. according to the manufacturer's instructions (Stratagene Co ⁇ .
  • the procedure is optimized as to nucleotide concentration, primer concentration, and template, so that the primers are inco ⁇ orated in an excess of nucleotide after 35 rounds of amplification or less.
  • the amplified fragment is purified, preferably on an agarose gel, a QiagenTM column or a spin column, to eliminate excess primers and incomplete product, both of which could otherwise act as competitive inhibitors.
  • the liposomal transfection procedure is optimized according to the manufacturer's instructions.
  • the enzyme or pe ⁇ etuation molecule concentration is optimized with respect to the optimum DNA/lipid in an appropriate buffer in the presence, or absence of the necessary divalent cation.
  • the enzyme is added to the nuclear acid molecule at or near 4°C, the enzyme- DNA solution is brought to room temperature, and the solution is combined with the lipid according to the manufacturer's instructions.
  • the gene delivery composition comprising the liposomal preparation, DNA and enzyme is added to the recipient cells for up to 24 hours.
  • the gene delivery composition comprising the liposomal preparation, DNA and enzyme is added to the cells for at least 5 hours prior to changing the media.
  • Other molecules may be inco ⁇ orated into the gene deliver composition of the invention. These molecules include poly L-lysine, poly ⁇ omithine. or other polycations for localization to the nucleus, adenovirus (or fusogenic peptide sequences) for endosmolysis, recombinase proteins to facilitate site-specific recombination and nuclear localization signals for efficient trafficking. Peptide recognition signals can be added to the poly L- lysine chains to facilitate nuclear transport of the nucleic acid molecule. Antibodies or other receptor-like molecules can be attached to the external surface liposome to facilitate delivery. Covalent attachment mechanisms can also be employed to tether the enzyme, DNA, or other molecules in reasonable proximity to each other.
  • enzymes can be modified by standard recombinant DNA methods familiar to persons skilled in the art, to include nuclear localization signals, endosmolytic peptides, or to facilitate cell entry, endosmolysis, intracellular trafficking, or entry into the nucleus (see Ausubel et al., Current Protocols in Molecular Biology, vols. 1 and 2, John Wiley and Sons, Inc.. 1994, 1995, 1996).
  • An important advantage of this embodiment of the invention is the lack of physical constraint upon the DNA size, due to the lack of a viral capsid. Another advantage is the absence of opportunities for replication competent retrovirus to form during industrial applications.
  • Example 4 Nucleic acid pseudotyping
  • a nucleic acid molecule is combined with a cationic lipid such as DOSPA:DOPE, allowing nucleic acid/lipid complexes to form.
  • the lipid/nucleic acid complexes are then combined with a retroviral supernatant or pellet, forming 3-way complexes with the retroviral particles.
  • the vims fuses with the cell, the nucleic acid/lipid complexes are also introduced into the cell.
  • the nucleic acid fragments e.g., a DNA fragment encoding a protein in which the DNA fragment is preferably terminated with retroviral integration signals, permit the virus to provide the pe ⁇ etuation molecule, e.g., reverse transcriptase/integrase.
  • the DNA fragment is then integrated more efficiently into the host cell chromosome.
  • the virus may act by facilitating entry of exogenous DNA into the cell by direct cytoplasmic fusion (avoiding the endosome. and possible lysosomal degradation of DNA), or it may facilitate integration via the attachment/integration sequences associated with the DNA fragments.
  • the association of virus, lipid, and DNA enhances the efficiency of long-term transfection/transduction after selection for the foreign gene with a drug such as puromycin (Table 2).
  • a retrovirus vector producer cell line (PA/RVBAG) containing the BAG vector ( Figure 3A) was incubated with a mixture of DNA/DOSPA:DOPE.
  • a DNA segment attached to the retrovirus vector as illustrated in Figure 3A contains a VL30 encapsidation signal (Hodgson, WO94/20608), a puromycin resistance gene and an SV40 vims early promoter, the murine att sequences are at its termini by oligonucleotides during amplification (see Figure 2D). After allowing the DNA/liposomes to associate with the vims, the mixture was permitted to infect human HT1080 fibrosarcoma cells.
  • Duplicate wells were selected with either the drug G418, to determine the neo gene titer of the BAG vector contained within the vims, or were stained with X-gal (to determine the comparative ⁇ -galactosidase titer of the virus being used). Liposomes increased the neo and ⁇ -gal titer of the BAG virus. Even in the most dilute samples of DNA/liposomes/vims (1/100 the DNA concentration of the transfected samples, or 2.5ng/well/l 00,000 cells) yielded puromycin resistant colonies (>10 6 puro-r colony/mg).
  • a DNA segment added to virus particles was efficiently transmitted and expressed, in the absence of retroviral LTRs. Moreover, because the DNA segment is presynthesized and not packaged within the virus capsid. some physical constraints upon vector size are removed. In addition, the lack of oncogenic retroviral LTRs provides an additional margin of safety against remobilization of the vector, replication competent viruses derived by recombination, and oncogene activation by the LTRs.
  • a therapeutic application of this vector would employ helper cell supernatant from a cell line such as PA317 that had not been transfected with a retrovims vector.
  • the simple DNA vector would be added to the "empty" retrovims preparation as described herein thus eliminating the retrovirus vector as a substrate for recombination leading to the production of replication competent vims.
  • the present invention enables those skilled in the art to introduce genes permanently and efficiently into cells using gene delivery compositions of the invention which combine liposomal preparations with viruses or other molecules.
  • the various embodiments of the invention either include biological virus particles or pe ⁇ etuation materials borne by virus particles, cells or mobile genetic elements.
  • Liposomal preparations of the invention can provide efficient entry of the virus or vector into a recipient cell. If synthetic vectors are employed (Example 3) most vector c/.v-acting sequences, such as long terminal repeats (except att sites) can be eliminated. This method has the additional advantage of reducing the exposure of the patient to biological entities, making gene therapy safer and more cost effective.
  • DNA segment or sequence A linear sequence comprised of any combination of the four DNA monomers.
  • Gene The smallest, independently functional unit of genetic material which codes for a protein product or controls or affects transcription and comprises at least one DNA segment or sequence.
  • Chimera A hybrid gene produced by recombinant DNA technology.
  • Phenotype A collection of mo ⁇ hological, physiological and/or biochemical traits possessed by a cell or organism.
  • Retrotransposon A cellular, movable genetic element with long terminal repeats.
  • Vector Usually an agent transmitting a disease or natural genetic information; here restricted to a genetic agent transmitting a foreign gene (DNA or RNA) constmct, unless other indicated.
  • Genome One set of chromosomes, haploid or diploid. for an agent or organism.
  • Transduction Here limited to the transmission of viral, retrotransposon, or exogenous (added) genes (unless otherwise indicated by means of viral particles or viral functions).
  • Helper Cell Line In this context, a cell line which has been genetically engineered or which naturally contains genes capable of generation of some or all necessary retroviral trims-acting functions or proteins, such as reverse transcriptase, viral core proteins, envelope glycoproteins, and/or tRNA for priming reverse transcription and the like.
  • helper cell lines include psi2 and PA317.
  • Replication Competent Retrovirus A retrovirus which bears all genes necessary for cis and trans functions; complete, able to replicate without additional viral functions.
  • Non-replication competent (defective) retrovirus A retrovims which requires supplemental functions in order to replicate, or which is unable to replicate by itself. In this context, it usually requires trans acting functions such as named above.
  • Transgene A foreign gene, usually inserted into a vector.
  • c ⁇ -acting element Genetic element which must be located on the same piece of nucleic acid in order to function, such as transcriptional pro ⁇ moter or enhance elements, primer binding sites and the like.
  • /r ⁇ /z-f-acting element Genetic element which need not be located in cis, i.e., that which may be located elsewhere, such as in the cellular genome (typically a protein encoding region).
  • trans elements are the retroviral core protein, polymerase, and envelope glycoprotein genes.
  • VL30 a retrotransposon type: virus-like 30S, found in several species of animals.
  • the DNA consists of long terminal repeats separated by 3-5 kb of internal DNA sequences, which are sometimes expressed in cellular RNA and are packaged into viruses of an infected cell or animal.
  • VL30 genomes tend to lack functional genes in the mouse.
  • VL30 sequences are found integrated at 100-200 copies in the chromosomal DNA of most Mus species.
  • Perpetuation Molecule a protein, such as an enzyme, or a nucleic acid molecule encoding such an enzyme, which permits the perpetuation of a gene of the invention within a cell, either by the integration of the gene into the host cell genome or through the autonomous replication of the gene within the host cell.
  • Gene amplification refers to any of a number of techniques for in vitro increasing the copy number of a genetic sequence.
  • PuXXATG refers to a translational start codon (ATG) which is preceded three base pairs by a purine base-containing nucleotide, making this ATG a favorable context for the start of translation.
  • Retro-vector any vector transmitted using reverse transcriptase to copy an RNA template into DNA (i.e., retrotransposon vectors, retrovims- derived vectors, synthetic vectors, or retroposon vectors,).
  • VPCs Vector producer cells
  • PA317/BAG and GP+env86/BAG producing the retroviral BAG vector were made from PA317 (amphotropic) and GP+env86 (ecotropic) packaging cell lines (cell lines from American Type Culture Collection, (ATCC), Rockville MD, and from Arthur Bank, Columbia University, New York. NY, respectively).
  • Retroviral vector stocks were shown to be replication-defective by marker rescue and amplification assays (Chakraborty et al., Biochem. Biophvs. Res. Commun.. 209. 677 (1995)).
  • the BAG retroviral vector (provided by Constance Cepko, Harvard University, Cambridge, MA) contains an E coli lac-Z gene (encoding ⁇ -galactosidase) expressed from the Moloney murine leukemia virus long terminal repeat and a bacterial neomycin phosphotransferase gene [neo) expressed from an internal SV40 virus early gene promoter, thus permitting detection either by ⁇ -galactosidase assay or by G418 dmg selection.
  • Vector producer cells (VPCs) were grown to near confluence in Dulbecco's modified Eagle's medium (DMEM) from GIBCO- BRL (Gaithersberg, MD) containing 10% fetal bovine serum (FBS).
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • Viral vector supernatant was harvested from VPCs either by centrifugation (3.000 X g. 5 minutes) or by filtration through 0.45 ⁇ m syringe filters (Costar. Cambridge. MA).
  • Target cells used to assay vector infectivity included murine NIH3T3 (ATCC # CRL1658) fibroblast and human HT1080 (ATCC # CCL121 ) fibrosarcoma cell lines. Both were grown in DMEM supplemented with 10% FBS.
  • target cells were seeded in multiwell plates at 100,000 per 3 cm tissue culture well on the day before infection, and were maintained in an atmosphere of 95% air/5% CO 2 at 35° C. Centrifuged or filtered viral supernatants (semm-containing medium) were mixed 1 : 1 with semm-free DMEM media containing varying amounts of LipofectamineTM (DOSPA:DOPE, GIBCO-BRL) or LipofectinTM (DOTMA:DOPE, GIBCO- BRL). DOTAP was added according to the manufacturer's instmctions (Boehringer-Mannheim, Indianapolis, IN).
  • the vims-lipid mixture was equilibrated at room temperature (22°C) for 30 minutes before being added to target cells.
  • Sterile polystyrene tubes were used exclusively during preincubation of virus and liposomes. In cases where polybrene (final concentration, 6 ⁇ g/ml) was used, it was either added to target cells prior to addition of vims-lipid preparations, or else it was added to the virus-lipid preparation at various times as indicated.
  • Medium was aspirated from target cells and was replaced by the virus-lipid preparations (0.5 ml) and supplemented with 2.5 ml of serum-containing medium (3.0 ml, total volume).
  • X-gal staining 5-bromo-4-chloro-3-indolyl- ⁇ -D- galactopyranoside, from Sigma Chemical Co., St. Louis, MO
  • G418 drug selection 600 ⁇ g/ml, active G418; GIBCO-BRL
  • Colonies were counted after 10 days of selection (G418 titer), or individual cells were counted 48 hours post-infection by X-gal staining ( ⁇ -gal titer).
  • ⁇ -gal titer blue cells were counted in a 1 mm-wide band across the plate both horizontally and vertically.
  • the cell counts listed reflect the raw data, which can be converted to colony-forming units/ml viral supernatant by multiplying by 141. Error bars indicate sample standard deviation.
  • Rapid assay for titer enhancement with cationic lipids 8-16 ⁇ l of Lipofectamine was added to 1 ml of serum free medium in a polystyrene tube. 1 ml of viral supernatant (containing serum) was combined with the lipid-containing medium at 20° C for 30-45 minutes. 0.25 ml of the mixture was added to 100,000 cells in a 3 cm tissue culture well, and 2.5 mis of serum containing medium was added to the cells. After 48 hours, the cells were stained with X-gal as described.
  • DNA pseudotype vector DNA was prepared by gene amplification using two oligonucleotide primers as reported in Figure 2 (melting temperature 72° C).
  • the primers contained the murine retroviral att sequences found at the termini of U3 and U5 sequences of the retroviral LTR.
  • the gene amplification product contained the entire VL30 packaging sequence of the vector VLPP (Hodgson, WO 94/20608) and the bacterial puromycin resistance gene expressed via the SV40 virus early gene promoter (see vector. Figure 3B2).
  • the polymerase chain reaction (PCR) product was purified by passage through a Worthington spin column to remove residual nucleotides and primers.
  • one set of the cells was stained with X-gal to determine the titer of the virus used, while two other sets were selected with either G418 (500 ⁇ g/ml, 10 days) or puromycin ( 1 ⁇ g/ml. 3 days) to determine the number of stably transmitted recipients.
  • G418 resistance indicated the relative efficiency of the virus vector (BAG) while puromycin resistance indicated the efficiency of the DNA vector.
  • ADDRESSEE Schwegman, Lundberg, Woessner ⁇ . Kluth, P.A.
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Abstract

L'invention concerne de nouvelles compositions servant à l'apport de gènes dans les cellules ainsi que leur mode d'application. Les compositions sont constituées de préparations liposomiales, de molécules d'acides nucléiques et de molécules de maintien. Elles favorisent l'introduction efficace et l'expression stable des gènes chimères se trouvant dans la molécule d'acide nucléique des cellules en fournissant des mécanismes spécifiques permettant de soutenir l'entrée, la circulation et l'intégration de ces molécules au sein des cellules. L'invention a l'avantage d'être plus efficace et plus sûre que les procédés viraux et confère en outre une stabilité d'expression que l'on ne pouvait obtenir qu'à partir des systèmes d'apport viraux.
PCT/US1996/002877 1995-02-28 1996-02-28 Vecteurs de virus biosynthetiques a usage en therapie genique WO1996026745A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96907918A EP0824362A1 (fr) 1995-02-28 1996-02-28 Vecteurs de virus biosynthetiques a usage en therapie genique
AU51353/96A AU5135396A (en) 1995-02-28 1996-02-28 Biosynthetic virus vectors for gene therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39535595A 1995-02-28 1995-02-28
US08/395,355 1995-02-28

Publications (2)

Publication Number Publication Date
WO1996026745A1 true WO1996026745A1 (fr) 1996-09-06
WO1996026745A9 WO1996026745A9 (fr) 1996-11-28

Family

ID=23562692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002877 WO1996026745A1 (fr) 1995-02-28 1996-02-28 Vecteurs de virus biosynthetiques a usage en therapie genique

Country Status (3)

Country Link
EP (1) EP0824362A1 (fr)
AU (1) AU5135396A (fr)
WO (1) WO1996026745A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056353A1 (fr) * 1997-06-13 1998-12-17 Navid Malik Systemes de vesicules lipidiques dotees d'une structure de support interne
US6916918B2 (en) 1997-08-04 2005-07-12 Cell Genesys, Inc. Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025673A1 (fr) * 1992-06-04 1993-12-23 The Regents Of The University Of California Therapie genique in vivo a l'aide d'une sequence significative sans intron
WO1994002178A1 (fr) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ciblage de liposomes sur la barriere hemato-encephalique
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5366737A (en) * 1985-01-07 1994-11-22 Syntex (U.S.A.) Inc. N-[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N,-tetrasubstituted ammonium lipids and uses therefor
US5470955A (en) * 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366737A (en) * 1985-01-07 1994-11-22 Syntex (U.S.A.) Inc. N-[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N,-tetrasubstituted ammonium lipids and uses therefor
WO1993025673A1 (fr) * 1992-06-04 1993-12-23 The Regents Of The University Of California Therapie genique in vivo a l'aide d'une sequence significative sans intron
WO1994002178A1 (fr) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ciblage de liposomes sur la barriere hemato-encephalique
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5470955A (en) * 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY, February 1990, Vol. 64, No. 2, INNES et al., "Cationic Liposomes (Lifofectin) Mediate Retroviral Infection in the Absence of Specific Receptors", pages 957-961. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056353A1 (fr) * 1997-06-13 1998-12-17 Navid Malik Systemes de vesicules lipidiques dotees d'une structure de support interne
US6916918B2 (en) 1997-08-04 2005-07-12 Cell Genesys, Inc. Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof

Also Published As

Publication number Publication date
AU5135396A (en) 1996-09-18
EP0824362A1 (fr) 1998-02-25

Similar Documents

Publication Publication Date Title
Hodgson et al. Virosomes: cationic liposomes enhance retroviral transduction
EP0670905B1 (fr) Virus recombines presentant un polypeptide non-viral sur leur surface externe
JP4190579B2 (ja) 非分裂細胞への核酸運搬のためのベクターおよび使用方法
JP4733166B2 (ja) ベクターおよびウイルスベクター、およびこれらを増殖するためのパッケージング細胞株
US5952225A (en) Retroviral vectors produced by producer cell lines resistant to lysis by human serum
CA2266423A1 (fr) Procedes permettant l'optimisation d'une therapie genique grace a un rearrangement et une selection recursifs de sequences
CA2268265A1 (fr) Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences
WO1998042856A9 (fr) Vecteurs et vecteurs viraux et lignees de cellules d'encapsidation les propageant
Van Tendeloo et al. Gene therapy: principles and applications to hematopoietic cells
US5580766A (en) Retroviral vector particles for transducing non-proliferating cells
Hodgson et al. Biosynthetic retrovectoring systems for gene therapy
EP0824362A1 (fr) Vecteurs de virus biosynthetiques a usage en therapie genique
EP0817860B1 (fr) Particules retrovirales pseudotypees
WO1996026745A9 (fr) Vecteurs de virus biosynthetiques a usage en therapie genique
US6130089A (en) Materials and methods for gene transfer
Adams et al. Infection by retroviral vectors outside of their host range in the presence of replication-defective adenovirus
US20060183228A1 (en) Viral vectors with surface or envelope components
US20070037284A1 (en) Vectors for expressing exogenous gene or exogenous nucleic acid sequences
CA2596292C (fr) Vecteurs et vecteurs viraux et lignees de cellules d'encapsidation les propageant
Taylor et al. Promotion of retroviral entry in the absence of envelope protein by chlorpromazine
Garoff et al. Alphavirus-Retrovirus Vectors
Garoff et al. Alphavirus-Retrovirus Vectors Henrik Garoff and Kejun Li Karolinska Institutet, Dept. of Biosciences at Novum 141 57 HUDDINGE, Sweden
Kaneda Chimeric Gene Delivery Systems
Beckert et al. Section ii other therapeutic Strategies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5,DRAWINGS,REPLACED BY NEW PAGES 1/8-8/8;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 860316

Date of ref document: 19970828

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996907918

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996907918

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996907918

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)